BioSpace

Alnylam bulls and bears fight it out after business-shaking guidance cut

While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.

By BioSpace

1 min read
Alnylam bulls and bears fight it out after business-shaking guidance cut
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights